Study Title

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

Study Details

Description:

To learn if giving 177Lu girentuximab in combination with cabozantinib plus nivolumab can help to control advanced clear cell renal cell carcinoma (ccRCC).

Sponsor:

MD Anderson Cancer Center

Contacts:

Eric Jonasch, MD (Principal Investigator)

ejonasch@mdanderson.org

(713) 563-7232

Government Study Link:

NCT05663710 - Click here to see study on

ClinicalTrials.gov

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468